Drawing for DYSBIOTIC THERAPEUTICS

USPTO serial 86575158

DYSBIOTIC THERAPEUTICS

Reviewed by CopyMark Law Group

Filing date
Status date
Registration date
—
Examiner
SCHWAB, CHAU CRISTIA H
Law office
TMO LAW OFFICE 110 - EXAMINING ATTORNEY ASSIGNED

What this means

These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.

Status 602: These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances.

Need help with DYSBIOTIC THERAPEUTICS?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Heather E. Balmat

HEATHER E. BALMAT Balmat Law Pllc977 Seminole TrlCharlottesville, VA 22901-2824UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005microbial preparations for pharmaceutical, veterinary and medical purposes; dietary supplements, nutritional supplements, nutraceuticals, food supplements, vegetable-based food beverages, and nutritional food bars containing microorganisms for medical therapeutic or preventative purposes; therapeutic pharmaceuticals containing microorganisms or derivatives of microorganisms for medical and veterinary use for the treatment or prevention of pre-neoplastic lesions, neoplasms, tumors, cancers, or metastases; pharmaceutical, veterinary and medical preparations and substances, namely, anti-microbial preparations and substances, anti-bacterial, anti-fungal, anti-viral, and anti- protistal preparations and substances; anti-cancer preparations and substances;: combination preparations of anti-microbials, microbial preparations, and anti-cancer preparations or inhibiting microbiological decomposition in food, beverages, animal feed and pharmaceuticals; pharmaceutical preparations and substances for the treatment of cancer, namely, microbial, anti- microbial, and anti-cancer for veterinary and medical use; pharmaceutical preparations for the treatment of infectious diseases and cancer, namely, combination preparations of anti- cancer agents, microbial preparations and anti-microbials preparations; diagnostic kits comprised of diagnostic reagents and buffers for the detection of microbes, viral, bacterial, fungal, and rotistal infections, inflammation, and biomarkers associated with pre-neoplastic lesions, neoplasms, tumors, cancers, or metastases; preparations for detecting mutations in genes for medical purposes as used in the collection of large-scale genomic, metagenomic, proteomic, transcriptomic, epigenetic, and metabolomic medical data and related clinical dataACTIVE—
009scientific, analytical, and statistical computer software for creating and managing databases containing genomic, metagenomic, proteomic, transcriptomic, epigenetic, and metabolomic data derived from patient clinical care information and medical research data; computer software for analyzing and creating statistical models derived from patient clinical care information and medical research data in the nature of genomic, metagenomic, proteomic, transcriptomic, epigenetic, and metabolomic dataACTIVE—
010medical diagnostic instruments for screening, assessing, and determining appreciate courses of treatment in relation to pre-neoplastic lesions, neoplasms, tumors, cancers and metastasesACTIVE—
042electronic data storage services, namely, electronic storage of large-scale genomic, metagenomic, proteomic, transcriptomic, epigenetic, and metabolomic data and related clinical data for treatment and diagnostic purposes; database, computer-readable program and software development services, namely, development of scientific, analytical, and statistical software and related databases for use in conjunction with genomic, metagenomic, proteomic, transcriptomic, epigenetic, and metabolomic data gathered from patient clinical care information and medical research data; scientific, chemical, biochemical and microbiological research; scientific research in the field of genetics and genetic engineering of microbes; scientific research in the field of genetic and molecular tests, including tests for microbial populations in vertebrate samples; research and development of therapeutic pharmaceuticals, consumer medical products, diagnostic equipment and prognostic tools consisting of genetically engineered microorganisms, combinations of microorganisms, and individually selected microorganisms for treatment and prevention of pre-neoplastic lesions, neoplasms, tumors, cancers and metastasesACTIVE—
044medical clinics; veterinary dentistry; behavioral analysis for medical purposes; genetic testing for medical purposes; collection and preservation of human blood for medical purposes; medical diagnostic testing for assessing pre-neoplastic lesions, neoplasms, tumors, cancers, or metastasesACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB2): The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.

DateCodeEventWhat it means
Jan 28, 2016MAB2ABANDONMENT NOTICE MAILED - FAILURE TO RESPONDThe trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.
Jan 28, 2016ABN2ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSEThe trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.
Jun 30, 2015GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 30, 2015GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 30, 2015CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 26, 2015DOCKASSIGNED TO EXAMINER—
Apr 2, 2015NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Mar 27, 2015NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance